Characteristic Patients with Multiple Myeloma at Dr. Kariadi Hospital Semarang

Santosa Iva(1*), Catharina Soeharti(2), Mika Lumban Tobing(3), Suyono Suyono(4), Eko Adhi Pangarsa(5)

(*) Corresponding Author


Background. Multiple myeloma (MM) is a malignancy of differentiated B-lymphocytes characterized by accumulation of clonal plasma cells in the bone marrow (BM), the presence of a monoclonal immunoglobulin (Ig) in the serum and/or urine, and osteolytic bone lesions. Complications of this disease consist of recurrent bacterial infection, anemia, osteolytic lesion and decreased renal function. 2-5 MM is the cause of death in 1% of cancer death in Western countries. MM incidence is 1% of all malignancies and 10% of hematologic malignancies in Caucasian race and 20% in the Afro American race.

Aim. The aim of the study is to know the descriptive data of characteristic of patients with MM at dr. Kariadi Hospital Semarang.

Method. Despite of development in patient management, MM is still an incurable disease, with 5-year survival rates lower than 40%. There are many differences in myeloma and its clinical manifestations. Some patients can survive in the months until over than 10 years.5, 6, 7 The median survival was 33 months, this number is similar in Asian studies.

Results. There are several prognostic factors in myeloma management, such as β2-Microglobulin (β2m), serum albumin, serum creatinine, plasma cell percentage in marrow, bone lytic lesion, anemia.10-13 β2m is a prognostic factor used by the International Staging System (ISS)11 to determine stadium and prognosis in MM. β2m correlates with other prognostic factors, such as serum creatinine, anemia, mechanism of bone destruction in MM patients.11,13

Conclusion. MM in Indonesia has not been studied comprehensively and the β2m measurement is expensive and not widely available.


Multiple Meyloma, bone marrow, prognostic factors

Full Text:



Drach J, Kaufmann H. New developments and treatment in multiple myeloma: new insights on molecular biology. ESMO 2002.

Bataille R, Harousseau JL. Multiple myeloma. N Enj J Med. 1997; 336 : 1657-1664.

Anderson KC, Kyle RA, Dalton. WS, et. al. Multiple myeloma: new insights and therapeutic approaches. Hematology 2002:147-165.

Dave SS, Dunbar CE. Multiple myeloma. In: Rodgers GP, Young NS. Bethesda handbook of clinical hematology. Philadelphia. Lippincott Williams & Wilkins. 2005: 221-231.

Dispenzieri A, Lancy MQ, Greipp PR. Multiple Myeloma. In: Greer JP, Foerster J, Rodger GM, et al. Editor, Wintrobe‘s clinical hematology, 12th Edition. Philidalphia, Lippincott Williams & Wilkins. 2009: 2372-2438.

Barillé-Nion S, Barlogie, Bataille R, et al. Advances in biology and therapy of multiple myeloma. Hematology 2003: 248-278.

Decaux O, Lodé L, Minvielle S, Avet- Loiseau H. Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival. [Pubmed: 17559979 ]

Kyle RA, Gertz MA, Witzif TE, et. al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78:21-33.

Zhong Fei, . Wei-jun FU, Zhen-gang Y et al. Prognostic factors and staging systems of multiple myeloma. Chinese Medical Journal 2007;119(19) :1689-1693.

Greipp PR, Katzmann JA, O’Fallon WM, Kyle RA .Value of β2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988:219-223.

Greipp PR, Miguel JS, Durie BGM et al. International staging system for multiple myeloma. J Clin Oncol 2005: 2(15);3412-

ultiple Myeloma: A practical guide to current management. The American School of Oncology. 2005.

Sharma S,Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008:14; 3262-3267.

Huang SY, Yao M, Tang JL et al. Epidemiology of Multiple Myeloma in Taiwan, Increasing Incidence for the Past 25 Years and Higher Prevalence of Extramedullary Myeloma in Patients Younger Than 55 Years. Cancer 2007; 110:896-905.

Free royal myeloma clinic

Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. Q J Med 2007; 100:635–640.

Zhong-fei T, Wei-jun F, Zhen-gang Y TAO Zhong-fei, FU Wei-jun, YUAN Zhen-ganget al. Prognostic factors and staging systems of multiple myeloma: a single center study in China. Chin Med J 2007;120(19):1655-1658 Rajkumar SV, Kyle RA. Multiple Myeloma:Diagnosis and Treatment. Mayo Clin Proc. 2005;80(10):1371-1382.

Bladé J, Rosiñol L, Moving forward in myeloma research. Haematologica 2004; 89(5):

United Kingdom Myeloma Forum. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. British Journal of Haematology 2004: 124; 717–726.

Grethlein SJ. Multiple Myeloma.

Yoshida M. Compromised immune function in multiple myeloma. Nippon Rinsho. 2007 Dec;65(12):2238-42 [Abstract, Pubmed]

Roodman GD. Mechanisms of bone resorption in myeloma. J Musculoskel Neuron Interact 2003; 3(4):271-272.

Birgegård G. Managing anemia in lymphoma and multiple myeloma. Therapeutics and Clinical Risk Management 2008;4(2): 527-539.


Article Metrics

Abstract views : 1579 | views : 1385


  • There are currently no refbacks.

Copyright (c) 2017 Acta Interna The Journal of Internal Medicine

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Acta Interna The Journal of Internal Medicine Indexed by:


 Indonesia Onesearch Google Scholar IPI Indonesian Publication Index

 website statistics View My Stats  



Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.